{"id":42153,"date":"2015-09-17T11:25:58","date_gmt":"2015-09-17T16:25:58","guid":{"rendered":"https:\/\/content.findlaw-admin.com\/ability-legal\/contracts\/uncategorized\/collaborative-research-agreement-gilead-sciences-inc-and-glaxo.html"},"modified":"2015-09-17T11:25:58","modified_gmt":"2015-09-17T16:25:58","slug":"collaborative-research-agreement-gilead-sciences-inc-and-glaxo","status":"publish","type":"corporate_contracts","link":"https:\/\/corporate.findlaw.com\/contracts\/operations\/collaborative-research-agreement-gilead-sciences-inc-and-glaxo.html","title":{"rendered":"Collaborative Research Agreement &#8211; Gilead Sciences Inc. and Glaxo Wellcome Inc."},"content":{"rendered":"<pre>                            AMENDMENT NO. 1\n                                  TO\n                  COLLABORATIVE RESEARCH AGREEMENT\n                    BETWEEN GILEAD SCIENCES, INC.\n                                 AND\n                        GLAXO WELLCOME INC.\n                      DATED DECEMBER 22, 1997\n\nThis Amendment No. 1 (the 'Amendment') to the Collaborative Research \nAgreement entered into as of the 25th day of March, 1996, (the 'Original \nAgreement'), is made by and between GILEAD SCIENCES, INC., a Delaware \ncorporation, having its principal place of business at 353 Lakeside Drive, \nFoster City, California, 94404 ('Gilead') and GLAXO WELLCOME INC., a North \nCarolina corporation, having offices at Five Moore Drive, Research Triangle \nPark, North Carolina 27709 ('Glaxo'), effective as of December 22, 1997.\n\nWHEREAS, the Parties desire to amend the Original Agreement regarding Section \n13.4 'Termination of Research Term by Glaxo.'\n\nNOW, THEREFORE, in consideration of the foregoing premises and of the mutual \npromises and covenants set forth below, for other good and valuable \nconsideration the receipt and sufficiency of which the Parties acknowledge, \nand in accordance with Article 16.7 of the Original Agreement allowing \nmodifications by written agreements duly signed by persons authorized to sign \non behalf of the Parties, the Parties, intending to be legally bound, agree \nas follows:\n\n1.  Unless otherwise defined in this Amendment, the capitalized terms used in \nthis Amendment shall have the same meaning as given them in the Original \nAgreement.\n\n2.  Article 13.4 shall be amended by deleting the first sentence of Article \n13.4 in its entirety and the following new first sentence of Article 13.4 \nshall be inserted in lieu thereof:\n\n    'Glaxo shall have the right to terminate the Research term prior to \n    expiration hereunder upon written notice to Gilead; provided, however, \n    that such termination be effective on the later of (a) June 22, 1998, or \n    (b) the date notice of termination pursuant to this Article 13.4 is given \n    to Gilead.'\n\n3.  Except as modified above, the Original Agreement shall remain in full \nforce and effect, including, but not limited to, the unamended provisions of \nArticle 13.4.\n\n\n\nIN WITNESS WHEREOF, the Parties have executed this Agreement, as of the day \nand year first above written.\n\nGILEAD SCIENCES, INC.                    GLAXO WELLCOME INC.\n\nBy:  \/s\/ John C. Martin                  By:  \/s\/ Robert M. Bell\n     ------------------------                 ------------------------\n\nName:  John C. Martin                    Name:  Robert M. Bell, Ph.D.\n     ------------------------                 ------------------------\n\nTitle:  CEO                              Title:  Vice President, Research\n                                                 Glaxo Wellcome Inc.\n     ------------------------                 ------------------------\n\n\n\n                                      -2-\n\n<\/pre>\n","protected":false},"template":"","meta":{"_acf_changed":false,"_stopmodifiedupdate":true,"_modified_date":"","_cloudinary_featured_overwrite":false},"corporate_contracts_companies":[7639,7645],"corporate_contracts_industries":[9405,9407],"corporate_contracts_types":[9613,9617],"class_list":["post-42153","corporate_contracts","type-corporate_contracts","status-publish","hentry","corporate_contracts_companies-gilead-sciences-inc","corporate_contracts_companies-glaxosmithkline-plc","corporate_contracts_industries-drugs__biotech","corporate_contracts_industries-drugs__pharma","corporate_contracts_types-operations","corporate_contracts_types-operations__jv"],"acf":[],"_links":{"self":[{"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts\/42153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts"}],"about":[{"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/types\/corporate_contracts"}],"wp:attachment":[{"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/media?parent=42153"}],"wp:term":[{"taxonomy":"corporate_contracts_companies","embeddable":true,"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts_companies?post=42153"},{"taxonomy":"corporate_contracts_industries","embeddable":true,"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts_industries?post=42153"},{"taxonomy":"corporate_contracts_types","embeddable":true,"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts_types?post=42153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}